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Viral antigens complexedwithmajor histocompatibility complex
(MHC) class Imolecules are recognized by cytotoxic T lymphocytes
on infected cells. Assays with synthetic peptides identify optimal
MHC class I ligands often used for vaccines. However, when natural
peptides are analyzed, more complex mixtures including long pep-
tides bulging in the middle of the binding site or with carboxyl
extensions are found, reflecting lack of exposure to carboxypepti-
dases in the antigenprocessing pathway. In contrast, precursor pep-
tides are exposed to extensive cytosolic aminopeptidase activity,
and fewer than 1% survive, only to be further trimmed in the endo-
plasmic reticulum.We show here a striking example of a nested set
of at least three highly antigenic and similarly abundant natural
MHC class I ligands, 15, 10, and 9 amino acids in length, derived
from a single human immunodeficiency virus gp160 epitope. Anti-
genprocessing, thus, gives rise to a richpool of possible ligands from
which MHC class I molecules can choose. The natural peptide set
includes a 15-residue-long peptide with unprecedented 6 N-termi-
nal residues that most likely extend out of the MHC class I binding
groove. This 15-mer is the longest natural peptide known recog-
nizedby cytotoxicT lymphocytes and is surprisingly protected from
aminopeptidase trimming in living cells.
Newly synthesized viral proteins are proteolytically processed before
MHC4 class I heavy chain-2m-peptide complex formation in the
lumen of the endoplasmic reticulum (ER) (1). Peptides of 8–10 residues
bind to MHC class I molecules usually by means of two major anchor
residues at positions 2 and C-terminal in the antigenic peptide (2, 3).
Somepeptidesmay be directly produced by the proteasome in their final
form, whereas others are generated as precursor peptides (4). These
precursor peptides must display the correct C terminus of the final
antigenic peptides, as the evidence suggests the absence of carboxypep-
tidases in the ER (1, 5). The limited number of studies on extraction and
identification of natural peptides derived from a known foreign antigen
shows that they constitute complex mixtures, mostly including C-ter-
minal extensions of the minimal epitope (6–9). On the contrary, pep-
tides are exposed to extensive cytosolic aminopeptidase activity, and
fewer than 1% of them survive and are rescued by the transporters
associated with antigen processing (TAP) and translocated into the ER
(10, 11).
In most cases it is assumed that the natural MHC class I ligand is the
one that has the canonical anchor sites, the minimal length, and the
optimal antigenicity when tested as synthetic peptide. N-terminal
extensions of such potential epitopes have been used to study trimming
by aminopeptidases purified from the ER or microsomal fractions.
There are several reports which show that the two enzymes, mouse
endoplasmic reticulum aminopeptidase associated with antigen proc-
essing (ERAAP)/human ERAP1 and human leukocyte-derived arginine
aminopeptidase (L-RAP)/ERAP2, can indeed trim the precursors to
yield the putative epitope in solution in the absence of the peptide-
binding MHC class I molecule and that they usually stop at around
8–9-aa-long products and in front of anX-proline bond (12–17). These
properties suffice to consider them bona fide trimming enzymes for
antigen presentation. There is also an intriguing report showing that
MHC class I molecules can direct this trimming (18), implying that
trimming might occur on the formed complex.
We have previously studied the natural peptides endogenously pro-
cessed in living cells from the HIV gp160 glycoprotein and presented by
the murine MHC class I molecule Dd (19). Unexpectedly, the natural
situation was more complex than having a single type of peptide-MHC
class I complex, as we found evidence of a nested set of two or three
equally abundant and equally antigenic peptides that differed in the N
terminus. This suggested the existence of an intracellular pool of pep-
tides derived from this natural protein in infected cells that are available
for binding to MHC class I molecules. The shortest natural Dd ligand
derived from gp160 is a 9-mer with the canonical anchor motifs for Ld
(20), and there were also some hints of a marginal in vivo Ld-restricted
CTL response to gp160 (21). This prompted us to study the natural Ld
ligands derived from this full-length viral protein to gain insight into the
nature of this pool of peptides and the mechanisms of antigen process-
ing and presentation.
The analysis of the natural Ld peptidic ligands resulting from the
endogenous processing of the envelope glycoprotein shows the pres-
ence of at least three differentMHC-peptide complexes in infected cells.
Two peptides coincide with those described in Dd (19), a 9-mer and a
10- or 11-mer. The third peptidic species corresponds to a 15-mer pep-
tide with an N-terminal extension of 6 residues, which probably pro-
trude out of the Ld binding groove. The 15-mer peptide binds to the
presenting molecule Ld, is recognized by 9-mer-selected CTL with an
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antigenicity only slightly lower than the optimal 9-mer, and is more
abundant in infected cells than this minimal epitope. The presence of
N-terminal extensions in all these high affinity natural ligands in the
face of an aminopeptidase activity at the site of complex formation
suggests that trimming cannot proceed once the complexes are formed.
This complexmixture of natural ligands for Ld parallels and expands the
natural ligands of Dd from the same epitope, suggesting that antigen
processing gives rise to a rich pool of possible ligands fromwhichMHC
class I molecules can choose. These results may have general implica-
tions for the rational design of vaccines.
EXPERIMENTAL PROCEDURES
Mice, Cell Lines, and Recombinant Vaccinia Viruses (rVV)—BALB/c
mice (H-2d haplotype) were bred in our animal facilities in accordance
with national regulations. All cell lines were cultured in Iscove’s modi-
fiedDulbecco’smedium supplementedwith 10% fetal bovine serum and
5  105 M -mercaptoethanol. The P13.1 cell line is a derivative from
mouse mastocytoma P815 cells (H-2d) by transfection with the lacZ
gene encoding -galactosidase (22). For infection, untransfected
murine kidney L cells (Ltk cells) and L cells transfected with Dd (23) or
Ld (24) were used. Transfectants with single and multiple mutations in
the sequence of the Ld molecule were also used (25). They were named
with the residue number followed by the single-letter code for the new
aa introduced. For stability assays, the TAP-deficient human lympho-
blastoid T2 cells transfected with Ld were employed (26). rVV-ENV
(vSC25) encodes the envelope glycoprotein gp160 from the strain IIIB of
HIV-1 under the control of the vaccinia early-late promoter 7.5k (27).
Its DNA sequence was confirmed. The HIV glycoprotein can be
detected byWestern blot, but its intermediate to low level of expression
precludes direct detection among the major proteins synthesized in the
infected cell. The parental Western Reserve strain was used as control.
Synthetic Peptides—Peptides were synthesized in a peptide synthe-
sizer (model 433A; Applied Biosystems, Foster City, CA) and purified
when needed by cation exchange (IE) and/or reversed-phase (RP)
HPLC. They were quantitated by A280 using peptide R10I as a standard,
and the identity was confirmed by matrix-assisted laser desorption/
ionization time of flight mass spectrometry. All peptide sequences are
derived from the sequence 313KIRIQRGPGRAFVTIGKIGN-
MRQAH337, which forms part of the V3-loop antigenic area from
HIV-1 strain IIIB envelope glycoprotein. They are named indicating the
first aa, the length, and the last aa. Thus, G9I refers to the nonamer of
sequence 319GPGRAFVTI327. The single-letter aa code is used through-
out. See Table 1 for an overview.
T Cell Lines and Cytotoxicity Assay—Polyclonal gp160-IIIB-mono-
specific CTL were generated by immunization of mice with rVV-ENV
followed byweekly restimulation of splenocytes withG9I synthetic pep-
tide and interleukin 2, as described (19, 28). They were used as effector
cells in standard 6-h cytotoxicity assays. As targets, L/Dd and L/Ld cells
were infected overnight with rVV as described (24). For peptide titra-
tions, targets and peptides were incubated for 20 min, and CTLs were
then added.
Isolation of Naturally Processed Peptides—L cells (3 109 in 30 roller
bottles) were infected with rVV at a multiplicity of infection of 3.5
plaque-forming units/cell, and 16 h later naturally processed peptides
were extracted from whole cells with trifluoroacetic acid, selected with
a Macrosep centrifugal concentrator (Filtron) with a cut-off of 10 kDa,
and purified by RP HPLC (19, 29). Control extractions were performed
identically, except that pellets of 109 P13.1 cells received 10 nmol of
synthetic peptides immediately after the addition of trifluoroacetic acid.
Pooled RP HPLC fractions that tested positive in cytotoxicity assays
with P13.1 target cells and gp160-specific CTLs were newly chromato-
graphed by IE HPLC chromatography in a Mono S column (19). Frac-
tions from this second column and dilutions thereof were analyzed in
new cytotoxicity assays. As the internal standard, a gp160-unrelated
peptide was included in all HPLC runs. To ensure comparability of
different runs, the actual conductivity gradient was always monitored.
Contamination of the HPLC columns was excluded by testing preced-
ing HPLC runs with CTL. Sometimes Dd-restricted CTLs were used in
these assays (but not in any other experiment included in this report),
because they showed an almost identical sensitivity to variations in pep-
tide sequence as the Ld-restricted CTL (compare Table 1 and Ref. 19).
For standardization, serial dilutions of synthetic peptides were tested
always in parallel.
Mass Spectrometry—HPLC fractions containing peptides from the
cellular extracts were sequenced by quadrupole ion trap electrospray
tandem mass spectrometry in a Deca XP LCQ mass spectrometer
(FinniganThermoQuest, San José, CA) (19). The charge and themass of
the ionic species were determined by high resolution sampling of the
mass/charge rank. Collision energy and ion-precursor resolution were
improved to optimize the fragmentation spectrum. Some synthetic pep-
tides derived from gp160 were analyzed, and their detection limit was 1
fmol (G9I), 10 fmol (R10I and Q11I), and 50 fmol (K15I).
MHC-Peptide Stability Assay—TAP-deficient T2 cells transfected
with Ld were cultured at 26 °C, and 14 h later they were washed and
incubated for 2 h at 37 °C with 500 M concentrations of the different
synthetic peptides, as described (19). After washing (time point 0), the
cells were further incubated at 37 °C. Aliquots removed at different time
points were stained with monoclonal antibody 30-5-7S, which recog-
nizes Ld bound to peptides (30), followed by flow cytometry. Cells incu-
bated without peptide had peak fluorescence intensities close to back-
ground staining with second Ab alone. Fluorescence index was
calculated at each time point as the ratio of peak channel fluorescence of
the sample to that of the control incubated without peptide.
TAP Transport Assay—ATAP translocation assay was performed as
described (31) using 5 106murineA20 cells permeabilizedwith strep-
tolysin O and the reporter peptide RYWANATRSF (R10F) that has an
acceptor sequence for glycosylation once transported into the ER (32).
R10F was labeled with 125I by using chloramine T (33), and ENV syn-
thetic peptides were used as competitors. Affinities of competitor pep-
tides were expressed as 1/IC50.
RESULTS
Differential Recognition Patterns of gp160-specific CTL Lines—In
BALB/c mice the CTL response against HIV-1 strain IIIB envelope gly-
coprotein is mainly restricted by the Dd class I molecule (34). A minor
Ld-restricted CTL population was previously described (21). To char-
acterize these responses gp160-specific CTL lines were generated that
selectively recognized gp160 peptides presented either by Dd or by Ld
(Fig. 1, A and B, respectively). Additional experiments performed with
three other Ld-positive cell lines confirmed the Ld-restricted recogni-
tion of the latter CTL line (data not shown). Endogenously synthesized
gp160 was also presented to either CTL line in cells that were infected
with a rVV that expresses the native glycoprotein, rVV-ENV (Fig. 1, C
and D). Generation of similar long term Ld-restricted gp160-specific
CTL lines by selection with the G9I peptide was achieved several times
over a period of several years. In accordance with published experience,
they were less easy to establish from BALB/c mice than Dd-restricted
gp160-specific CTL lines.
Titration curves with different synthetic peptides using L cells trans-
fectedwithDd or Ldwere performed. The nonamerG9I, which contains
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the canonical anchor residues for binding to Ld, was compared with
peptideswithN-terminal extensions (R10I) and deletions (P8I andG7I).
G9I andR10Iwere equally efficiently recognized, whereas P8Iwas 1000-
fold less antigenic, and G7I was not recognized (Table 1).
Comparable Presentation of gp160 Peptides by Mutants of the Ld
Molecule—L cells transfected with different mutants of the Ld allele
were used to characterize the Ld-restricted response against gp160. The
altered positions in each cellular line are detailed in its respective plot in
Fig. 2 and include both single and multiple mutations located in the
peptide binding groove. Theywere chosen tomimic the six changes that
exist between Ld and Lq, its closest allele (25). Thus, the cells that have
the six positions altered actually express Lq.
Titration curves of G9I and R10I synthetic peptides are shown in Fig.
2. The mutation in residue 116 was the one that singly affected most
presentations byMHC class I and recognition by the T-cell receptor. Its
negative effect was not compensated by any additional mutation, as all
transfectants with additional mutations besides that at 116 were nega-
tive. Changes at positions 95 and 97, also located on the floor of the
groove as residue 116, caused a milder 10–100-fold decrease in antige-
nicity. Residue 116 might be more critical because it contributes to
pocket F that hosts the C terminus of the peptide (35) and that has been
found also to affect CTL recognition of other epitopes presented by Ld
(25). Recognition of rVV-ENV-infected transfectants with mutations at
residues 116, 95, and 97 was clearly less efficiently than with the wild-
type presenting molecule (data not shown), supporting the synthetic
peptide data.
The same pattern of recognition was observed in all cases for both
R10I and G9I peptides (Fig. 2). None of the mutations in the presenting
molecule differentially affected presentation of either one of these enve-
lope synthetic peptides to specific CTL. The simplest model to account
for this observation is that both peptides bind with a similar conforma-
tion to Ld, as all Ld mutations had the same effect on presentation of
either peptide. Because G9I has the canonical length and P2 and P9
anchor residues to Ld, the data suggest that peptide R10I binds as G9I
does and that the R residue in R10I extends N-terminally out of the
MHC class I binding groove.
Physiological Processing Generates at Least Three Different Ld-associ-
ated Peptidic Species—To identify the natural endogenously processed
peptides of the gp160 glycoprotein that are associated with Ld, the pep-
tides generated after infection of L/Ld cells with rVV-ENV were acid-
extracted. The peptides were separated by RP HPLC, and the fractions
collected were analyzed in a cytotoxicity assay, detecting a broad anti-
genic peak (data not shown). Whole cells rather than antibody-selected
Ld cells were used for natural peptide extraction in order not to exclude
potential precursor peptides. Because of this, it was interesting to test
whether this antigenic activity was detected only when the Ld molecule
was present. Consequently, extraction experiments were carried out
using the Ld-negative parental Ltk cells using similar infected cell
equivalents as tested previously with Ld-positive cells. No antigenic
peaks were found in the RP HPLC runs from infected Ltk cells (data
not shown) (19). These results indicate that peptides generated by
endogenous processing of the envelope glycoprotein in infected L/Ld
cells must be bound to the presenting Ld molecule and are, therefore,
neither free from MHC nor bound also to the endogenous H-2k mole-
cules of L cells.
TABLE 1
Functional properties of synthetic peptides and overview of results
Synthetic peptide Terminia Coelution with




stabilitydName Sequence N end C end
G9I GPGRAFVTI 1st  
P8I PGRAFVTI Deleted 1st  
G7I GRAFVTI Deleted 1st  
G10G GPGRAFVTIG Extended 1st  NDe
R11G RGPGRAFVTIG Extended Extended 2nd  ND
Q12G QRGPGRAFVTIG Extended Extended 2nd  ND
G11K GPGRAFVTIGK Extended None f ND
R12K RGPGRAFVTIGK Extended Extended None f ND
I14K IQRGPGRAFVTIGK Extended Extended 2nd  ND
R15K RIQRGPGRAFVTIGK Extended Extended 3rd ND 
R10I RGPGRAFVTI Extended 2nd  
Q11I QRGPGRAFVTI Extended 2nd  
I12I IQRGPGRAFVTI Extended None  
R13I RIQRGPGRAFVTI Extended None  
K15I KIRIQRGPGRAFVTI Extended 3rd  
G9I-A GAGRAFVTI 1st ND 
R10I-A RGAGRAFVTI 2nd ND 
K15I-A KIRIQRGAGRAFVTI 3rd ND 
aThe terms deleted or extended are in reference to the termini of the highlightedG9I peptide (first peptide in theTable). The name and coelution of all natural peptides identified
in this study are highlighted.
bThree antigenic peaks were detected in IEHPLC runs of infected cell extracts, as shown in Fig. 3, and are referred here to as the 1st, 2nd, and 3rd peaks.When synthetic peptides
were individually analyzed by IEHPLC, their elution in any of the fractions of any of these peaks is scored here as coelution.Most peptideswith 1, 2, or 4 positive charges coelute
with the 1st, 2nd, or 3rd peak, respectively (19).
c Peptides were serially diluted in 10-fold steps and sequentially incubated with targets and CTL. Each additional  sign indicates a 10-fold higher antigenicity of the respective
peptide.
d Relevant MHC/peptide stability assays are displayed in Fig. 5.
e ND, not done.
f A peptidyl-carboxydipeptidase activity present in fetal calf serum removes the GK C-terminal extension (19, 37) and artificially improves antigenicity.
FIGURE 1. Different MHC-restricted CTL populations recognize gp160. L/Dd and L/Ld
target cells, preincubated (Œ, F) or not (, f) with 105 M G9I, were used in cytotoxic
assays with gp160-specific CTL lines. Recognition by a Dd-restricted (A) or by a Ld-re-
stricted (B) CTL line is shown. L/Dd (C) or L/Ld cells (D) were infected or not with 10
plaque-forming units/cell of rVV-ENV (E) or with the negative control Western Reserve
(WR) () and assayed with Dd-restricted CTL or Ld-restricted CTL, respectively.
Natural N-extended Nested Set of MHC Class I Ligands
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Even though the gradient used for elution of the natural peptides
from the RPHPLC columnwas rather flat, several different overlapping
synthetic peptides from the antigenic region encompassing gp160 resi-
dues 313–337 eluted within the antigenic peak (data not shown). This is
probably because all these peptides have related, low hydrophobicity, as
all of them are positively charged. To determine the peptidic species
present in the antigenic peak obtained in the RP HPLC analysis of
infected cells, the pool of positive fractions was further separated by IE
HPLC. The fractions were again analyzed by cytotoxicity assays. Fig. 3
shows three different antigenic peaks generated as a result of the endog-
enous processing of the envelope glycoprotein in L/Ld cells.
The first antigenic peak (fractions 21–23) coelutes with mono-
charged species. Quadrupole/ion trap mass spectrometry analysis
showed that fractions 21–23 recognized by CTL unequivocally con-
tained G9I peptide (Fig. 4). Mass spectrometry fragmentation of the
synthetic peptide G9I gave a very similar fragmentation profile, con-
firming identification (data not shown). Thus, the optimal and minimal
G9I is a natural Ld ligand in infected cells.
The second peak in Fig. 3 (fractions 36–40) from infected L/Ld cells
mainly groups some bi-charged peptides. These first two peaks surpris-
ingly correspond to the elution times of the peptides derived from this
epitope that we have previously described as natural Dd ligands (19). As
in that report, five candidate coeluting synthetic peptides that contained
the minimal G9I antigenic core were considered. Three, R11G, Q12G,
and I14K, were excluded as natural Ld ligands because they were not
recognized as synthetic peptides byCTL (Table 1). In contrast, the other
two candidate synthetic peptides coeluting with the second peak in Fig.
3, the singly and doubly N-terminal-extended peptides R10I and Q11I,
were as antigenic as theminimal G9I nonamer (Fig. 5A). Unfortunately,
attempts to identify R10I or Q11I peptides (both with two charges)
analyzing the second antigenic peak by mass spectrometry were com-
promised by the lack of sensitivity. Indeed, fragmentation of synthetic
R10I and Q11I peptides is at least 10-fold less efficient than that of
synthetic G9I (see “Experimental Procedures”). The presence of an
additional Arg in these two peptides as compared with G9I may have
contributed to further decreased efficiency of detection of fragmented
ions, already close to the detection limit for the natural G9I peptide. An
even stronger lack of sensitivity also compromised positive identifica-
tion of K15I by mass spectrometry (see next paragraph). We concluded
FIGURE 2. Identical effect of mutations in the Ld molecule on exogenous presenta-
tion of gp160 synthetic peptides. L cells transfected with the Ld molecule or with
mutants in different residues as indicated were incubated with serial dilutions of G9I (F)
or R10I (Œ) synthetic peptides and then with Ld-restricted CTL at an E:T ratio of 10:1.
FIGURE 3. At least three natural peptides generated by endogenous gp160 antigen
processing. Peptides extracted from rVV-ENV-infected L/Ld cells were separated by RP
HPLC. Antigenic fractions 13–22 from this column were pooled and separated by IE
HPLC. This was followed by a cytotoxicity assay of the collected fractions. The results
obtained with 1.5  108 (F), 0.18  108 (Œ), and 0.09  108 (f) cell equivalents of the
peptide extracts are plotted. At the right, the secondary scale indicates the monitored
conductivity of the NaCl gradient (dotted line) employed for elution.
FIGURE 4. Identification by mass spectrometry of G9I in infected cell extracts. Tan-
dem mass spectrometry fragmentation spectrum obtained after quadrupole ion trap
mass spectrometry of fraction 22 of the IE HPLC run of extracts of L/Ld cells infected with
rVV-ENV and shown in Fig. 3. The bicharged parental ion corresponding to the G9I pep-
tide has a mass/charge ratio of 458.4 (arrow). Ions generated in the fragmentation are
detailed, whereas the sequence deduced from the indicated fragments is shown in the
lateral box.
FIGURE 5. Antigenicity and MHC stability assay of several gp160 synthetic peptides.
A, recognition by CTL of titration curves of G9I (F), R10I (Œ), Q11I (f), and K15I ()
synthetic peptides on L/Ld cells. B and C, stability of cell surface MHC-peptide complexes
on TAP-deficient T2/Ld cells was assessed by flow cytometry. , R15K. Bars, S.D.
Natural N-extended Nested Set of MHC Class I Ligands
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that either R10I or Q11I or both are naturally processed and presented
by Ld in infected cells.
An Unexpectedly Long, N-terminal-extended Peptide Is Physiologi-
cally Processed from HIV-1 Envelope Protein—Finally, the third anti-
genic peak extracted from infected cells and shown in Fig. 3 (fractions
59–60) coelutes with several V3-loop synthetic peptides with as many
as 4 positive charges. This constitutes a set of 18 different candidate
coeluting synthetic peptides 15–20 aa in length that contain the mini-
malG9I antigenic core. All have doubleN- andC-terminal extensions of
the optimal G9I natural ligand, with the single exception of peptide
K15I, with a 6-aa N-terminal extension. Analysis started with the latter.
Fig. 5A shows that synthetic K15I was only 10-fold less antigenic for
G9I-selected CTL that the core G9I peptide. This suggested that K15I
may be the naturally processed peptide in this HPLC peak. Because it is
an unexpectedly long candidate MHC class I ligand, we made sure that
no traces of contamination with other antigenic peptides were respon-
sible for this high antigenicity. Even after overloading an IE HPLC col-
umn, all activity coeluted with the single A280 peak of the purified K15I
peptide (Fig. 6A).
We next used TAP-deficient T2 cells transfected with Ld to assay the
relative stability of the MHC class I complexes with the different gp160
peptides. It was found that G9I, R10I, Q11I, and K15I peptides induced
similar numbers of similarly stable Ld-peptide surface complexes (Fig. 5,
B and C).
Exchange for alanine of the proline residue that serves as the canon-
ical anchor abolished interaction with Ld of the N-extended K15I and
R10I peptides as well as of G9I (Table 1). This indicates that they bind to
Ld using the canonical anchors and, thus, with anN terminus extending
out of the Ld peptide groove. Binding to severalMHC class I allotypes of
non-natural peptides with N-terminal extensions out of the groove has
been shown before to be tolerated without significant rearrangement in
the MHC structure (36). Other peptides with N-terminal extensions
shorter than the 6 aa, present in K15I but that did not coelute with any
natural antigenic activity from infected cells, were also remarkably anti-
genic for the G9I-selected CTL lines (Table 1), strongly supporting that
K15I and the other extended variants bound to Ld and were recognized
by CTL in the same conformation as R10I and G9I. Collectively, these
results strongly suggest that K15I is naturally processed and presented
by Ld in infected cells expressing HIV ENV.
As opposed to K15I, N-extended peptides I14I and R13I as well as
I12I, which lack one or two positive charges with respect to K15I,
respectively, could be excluded as natural peptides. Indeed, no antigenic
activity was found around fraction 45 or 30 of the IE HPLC run of the
infected cell extracts (Fig. 3), where they elute, respectively.
The remaining four-charged synthetic peptides coeluting with the
third antigenic peak in Fig. 3 had both N- and C-terminal extensions.
The shortest was R15K and was analyzed next. As a synthetic peptide,
R15K did not coelute with the antigenic peak in the RP HPLC column
that was run as the first purification step of the infected cell extracts. In
addition, in contrast to K15I, R15K formed complexeswith Ldwith poor
efficiency (Fig. 5C). Moreover, part of its activity is actually due to con-
version to the more antigenic R13I peptide by an angiotensin-convert-
ing enzyme-like present in serum. This carboxy-dipeptidase activity
removes pairs of C-terminal residues, as described previously (37) and
confirmed by us by IEHPLC (data not shown). This was also the case for
other peptides with the same two-residueGK carboxyl extension (Table
1, footnote d) but not for K15I (data not shown). Peptides with this ENV
sequence and with C-terminal extensions longer than 2 aa do not profit
from angiotensin-converting enzyme activity to enhance their increas-
ingly poorer antigenicity (38). Already, a single C-terminal extension of
the minimal G9I peptide, as in peptide G10G, showed the lack of toler-
ance of Ld and CTL to such extensions (Table 1). As expected, several
peptides with double N and C extensions were also very poorly pre-
sented by Ld (Table 1). Because of this, we excluded R15K and all other
longer, doubly extended, 4-charged peptides as potential natural pep-
tides. In summary these results support the conclusion that, in addition
to G9I and R10I/Q11I peptides, the N-terminal-extended K15I peptide
is a natural Ld ligand derived from HIV envelope glycoprotein.
Serial dilutions of IE HPLC antigenic fractions indicated comparable
antigenic activity for all of them (Fig. 3). Because G9I, R10I, and Q11I
were similarly recognized by Ld-restricted CTL, whereas K15I was
10-fold less efficiently recognized, the results suggest that gp160-de-
rived Ld ligands comprise equivalent amounts of the former three pep-
tides and around 10-fold more of the much longer K15I peptide. It is
uncertain which fraction of each peptide-MHC complex is located
intracellularly or at the cell surface as infection proceeds.
The Shorter Peptidic Species Are Not Generated from the Longer Ones
by the Extraction Procedure—Because theK15I natural peptide contains
and is longer than the mono-charged G9I and the two bi-charged pep-
tides, the latter three could potentially be artificially generated from
K15I by an aminopeptidase activity or by a chemical reaction during the
biochemical isolation of naturally processed peptides. To exclude this
possibility, similar extraction experiments as those performed with
rVV-ENV-infected cells were carried out with K15I-pulsed Ld-positive
target cells. After RP and IE HPLC, collected fractions from this control
experiment were tested with CTL. Activity was only detected at the
expected elution position for K15I. No production of shorter peptides
was found (Fig. 6B). In addition, in a similar experiment with R10I and
Q11I synthetic peptides, no evidence of generation of G9I from these
two peptides during extract preparation nor alteration of the IE HPLC
FIGURE 6. The long synthetic peptide K15I is not contaminated and is not modified
by the extraction procedure. A, purified peptide K15I (0.52 nmol) was separated by IE
HPLC and monitored by A280 (solid line), and fractions were collected and assayed with
CTL (F) at a resulting concentration per assay well of 105 M. The elution positions of G9I
and bicharged R10I or Q11I peptides are also indicated. At the right, the secondary scale
indicates the monitored conductivity of the NaCl gradient (dotted line) employed for
elution. B, peptides were extracted from uninfected Ld-positive P13.1 cells to which 0.59
nmol of synthetic K15I had been added before extraction and separated by RP HPLC.
Antigenic fractions were selected, further separated by IE HPLC, and tested with CTL.
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elution pattern was observed either (data not shown) (19). These data,
thus, confirm the endogenous generation of G9I and R10I or Q11I in
rVV-ENV-infected cells, reinforcing their identification as candidate
natural peptides in infected cells.
Transport to the ER by TAP—Next, efficiency of TAP-mediated
transport into the ER of all peptides with 1–6-aa N-terminal extensions
was assayed in vitro. As shown in Fig. 7, all peptides were transported by
TAP with a low to intermediate affinity. Of note, two of the natural
ligands, G9I and K15I, were among the peptides least efficiently trans-
ported by murine TAP but still with an affinity compatible with their
physiological transport in infected cells (39).
DISCUSSION
The analysis of the natural Ld peptidic ligands resulting from the
endogenous processing of the HIV envelope glycoprotein shows the
presence of at least three different MHC-peptide complexes in infected
cells. The first peptide is identified by mass spectrometry as the
nonamer G9I (319GPGRAFVTI327) with the canonical anchor motif for
binding to Ld at positions 2 and 9. The second species corresponds to the
N-terminal-extended R10I 10-mer or Q11I 11-mer, which are as anti-
genic and abundant as the canonical G9I. The third peptidic species
corresponds to the 15-mer K15I peptide, the longest MHC class I nat-
ural ligand recognized by CTL described so far. The peptide has an
N-terminal extension of 6 residues, binds to the presenting molecule Ld
with an antigenicity for G9I-selected CTL only slightly lower than the
optimal 9-mer, and is more abundant in infected cells than the minimal
epitope.
To our knowledge this is the first report of such a complex N-
extended nested set of natural peptides with related antigenicity,
including such a long naturally processed antigenic peptide, K15I.
The underlying reason for our findings may be the exceptionally high
affinity for Ld of the longer N-terminally extended gp160 peptides.
Although Ld seems to need trimming by ERAAP for providing
roughly one-half of its regular epitopes (13), the K15I to R10I pep-
tides would rather contribute to the fraction of ERAAP-independent
complexes, as they are spared from trimming in vivo and presented
by Ld. Thus, ERAAP-independent MHC class I ligands appear to
include not only peptides already produced in their final size in the
cytosol but also long high affinity peptides as the two/three identified
in this report. Therefore, the working hypothesis is that these N-
extended peptides will escape trimming because they bind faster and
more quantitatively to Ld than do other sets of lower affinity ex-
tended epitopes to other MHC class I allotypes, as shown for an
undecapeptide (31). Further possible contributing factors might be
the long ER residence time of Ld as well as the lack in murine cells of
the counterpart gene for human ERAP2, which by synergizing with
ERAP1 increases the efficiency of trimming this HIV epitope in vitro
(17). The presence of N-terminal extensions in all these high affinity
natural ligands in the face of an aminopeptidase activity at the site of
complex formation indicates that trimming, at least for the HIV ENV
N-extended peptides described here, cannot proceed significantly
once the complexes are formed.
Although this is the first report of an N-terminal- elongated nested
set of natural MHC class I ligands, there are six previous reports of
C-terminal-elongated peptides that also appear to bind to MHC class I
molecules with protruding extensions (7, 8, 40–43). This appears as a
natural consequence of the reported absence of C-terminal trimming
activity in the ER (1, 5). As opposed to our results, the antigenicity of the
elongated peptides was either not tested or at least 250-fold lower than
that of the standard minimal peptide, which leaves open their quantita-
tive contribution to theCTL response. Notably, five of the six reports on
C-terminal extensions involve human MHC ligands, mostly of A2. In
contrast, this report reveals N-terminal-extended natural ligands in
murine cells. It is intriguing to recall that human cells have an additional
gene for an aminopeptidase, ERAP2 (16), that operates in a concerted
fashion with ERAP1 (17). Thus, it is uncertain whether high affinity
N-extended long peptides similar to those described by us in this report
and suggested previously (19) will also quickly and efficiently be pro-
tected from trimming byMHC class I molecules in human cells. There-
fore, it remains to be established whether this abundant presence of
highly antigenic N-terminal-extended ligands is an exceptional behav-
ior of Ld, whether it is more general to mouse cells and MHC class I
molecules, or whether it extends to other species.
We identified peptides with 1–2- and 6-aa-long N-terminal exten-
sions of the minimal and optimal HIV epitope as natural Ld ligands. It
was surprising that those peptides with 3- or 4-aa extensions, namely
I12I, and R13I, which were as antigenic as the natural ligands, were not
present in infected cells. Transport by TAP did not seem to be very
discriminating in this regard. The N-extended natural peptides per-
sisted despite ER trimming. In addition, at least the spectra of products
generated in vitro either by human ERAP1 alone or by ERAP1 and
ERAP2 (17) do not coincide with the spectrum and relative abundance
of natural peptides that we found in infected cells. Thus, we conclude
that it is more likely that ER aminopeptidase trimming does not play a
major role in determining the composition of the pool of natural Ld
ligands derived from this epitope. We suggest that cytosolic processing
and trimming coupled with resistance to cytosolic degradation (11, 44)
are probably the major determinants of the final composition of gp160-
derived peptides presented by Ld.
The most notable exception was peptide R13I, which is transported
best, most resistant to trimming (17), and as antigenic as the natural
ligand K15I. Yet, it is not a natural Ld ligand because it does not coelute
with any natural antigenic peak. Thus, it is probably neither produced in
the cytosol nor in the ER. Otherwise, it would have probably bound to
Ld. Simple experiments with synthetic peptides would have qualified
R13I as a very probable natural peptide. Thus, it represents a paradigm
where analysis of natural endogenous peptides is critically required to
unequivocally establish the physiological relevance of a group of very
antigenic synthetic peptides.
The complex mixture of natural nested ligands for Ld parallels and
expands the natural ligands ofDd from the same epitope (19), suggesting
that antigen processing gives rise to a rich pool of possible ligands from
which MHC class I molecules can choose. In these two examples we
show at the same time the extended diversity of peptides generated by
FIGURE 7. Transport by TAP. The indicated synthetic peptides were assayed for trans-
port by murine TAP in an in vitro competition assay. Affinities of competitor peptides are
expressed as 1/IC50.
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processing (45) as well as the limitations imposed by the selectivity of
the combined specificities of the generative and destructive proteases in
the antigen processing pathway (43). The existence of a collection of
potentialMHC ligandsmay underlie the promiscuous presentation by 5
human, 1 chimpanzee, 1 macaque, and 6 murine MHC class I allotypes
of peptides from this very sameHIV epitope (46). Our results emphasize
the complexity of antigen presentation, which is sometimes minimized
in epitope detection assays with synthetic peptides. It remains to be
provenwhether nested sets of natural peptides are the rule or the excep-
tion. It is important to note that, as opposed to the generalized use of low
resolution, single columnHPLC in our recent reports and in some of the
best characterized C-terminal-extended nested sets of peptides (8, 43),
high resolution HPLC techniques have been applied. However, it is also
true that extensions by as little as one residue on either end of the
peptide usually result inmarked drops in affinity toMHC.Herewe show
that a 10-fold drop in antigenicity as in the K15I natural ligand is com-
patible with abundant MHC-peptide complexes in vivo.
Analysis of the cellular peptides eluted from Ld molecules was
restricted to those 8–11 aa in length (20). Yet, only 9- or 10-aa-long
peptideswith both P2 and carboxyl anchorswere identified that differed
only in the degree of central bulging. This is themost frequent structural
adaptation for accommodating peptides up to 14 residues in length and
with good affinity by MHC class I molecules (9, 42, 47–51) and always
has a drastic effect on CTL recognition, giving rise to fully new CTL
specificities. Thus, the occurrence of K15I and R10I or Q11I as natural
peptides would not have been predicted from these reports. Several
lines of results indicated that R10I binds with the same anchors as the
canonical G9I, with the N-terminal Arg residue extending out of the
groove. The lack of alternative anchor motifs to Ld as well as the high
antigenicity of K15I with G9I-selected CTL also strongly suggests this
mode of binding. Because the K15I N-extended sequence of six residues
is very polar, it may be stable in solution without additional interactions
with the external regions of the Ld 1 and 2 domains or, later, with the
T-cell receptor although these are not ruled out andmight contribute to
complex stability and antigenicity.
Perhaps themost relevant aspects of our work are the abundant pres-
ence of several N-terminal-extended MHC class I ligands in the face of
ER aminopeptidase activity as well as the high diversity of physiological
MHC-peptide complexes. Because we obtain CTL restricted by Ld or by
Dd from the same animal, we assume that several or all 5–7 natural
peptide-MHC complexes may be present simultaneously in infected or
cross-presenting cells in vivo. This would clearly be an advantage for the
immune system, particularly to avoid focusing the CTL response to few
complexes, which favors the appearance ofCTL escape virusmutants. A
detailed knowledge of MHC class I peptide ligands and their intracellu-
lar generation should be relevant in the development of an HIV vaccine
including CTL epitopes.
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28. López, D., Gil-Torregrosa, B. C., Bergmann, C., and Del Val, M. (2000) J. Immunol.
164, 5070–5077
29. Del Val, M., Schlicht, H. J., Ruppert, T., Reddehase, M. J., and Koszinowski, U. H.
(1991) Cell 66, 1145–1153
30. Ozato, K., Hansen, T. H., and Sachs, D. H. (1980) J. Immunol. 125, 2473–2477
31. Lauvau, G., Kakimi, K., Niedermann, G., Ostankovitch, M., Yotnda, P., Firat, H.,
Chisari, F. V., and van Endert, P. M. (1999) J. Exp. Med. 190, 1227–1240
32. Momburg, F., Roelse, J., Howard, J. C., Butcher,G.W.,Hammerling,G. J., andNeefjes,
J. J. (1994) Nature 367, 648–651
33. van Endert, P. M., Tampe, R., Meyer, T. H., Tisch, R., Bach, J. F., andMcDevitt, H. O.
(1994) Immunity 1, 491–500
34. Takahashi, H., Cohen, J., Hosmalin, A., Cease, K. B., Houghten, R., Cornette, J. L.,
DeLisi, C., Moss, B., Germain, R. N., and Berzofsky, J. A. (1988) Proc. Natl. Acad. Sci.
U. S. A. 85, 3105–3109
35. Balendiran,G. K., Solheim, J. C., Young,A.C.M.,Hansen, T.H.,Nathenson, S.G., and
Sacchettini, J. C. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6880–6885
36. Achour, A., Michaelsson, J., Harris, R. A., Odeberg, J., Grufman, P., Sandberg, J. K.,
Levitsky, V., Karre, K., Sandalova, T., and Schneider, G. (2002) Immunity 17, 757–768
37. Kozlowski, S., Corr, M., Takeshita, T., Boyd, L. F., Pendleton, C. D., Germain, R. N.,
Berzofsky, J. A., and Margulies, D. H. (1992) J. Exp. Med. 175, 1417–1422
38. Kozlowski, S., Corr, M., Shirai, M., Boyd, L. F., Pendleton, C. D., Berzofsky, J. A., and
Margulies, D. H. (1993) J. Immunol. 151, 4033–4044
39. Daniel, S., Caillat-Zucman, S., Hammer, J., Bach, J. F., and van Endert, P. M. (1997)
J. Immunol. 159, 2350–2357
40. Frumento, G., Harris, P. E., Gawinowicz, M. A., Suciu-Foca, N., and Pernis, B. (1993)
Cell. Immunol. 152, 623–626
41. Collins, E. J., Garboczi, D. N., and Wiley, D. C. (1994) Nature 371, 626–629
42. Chen, Y., Sidney, J., Southwood, S., Cox, A. L., Sakaguchi, K., Henderson, R. A.,
Appella, E., Hunt, D. F., Sette, A., and Engelhard, V. H. (1994) J. Immunol. 152,
2874–2881
43. Serwold, T., and Shastri, N. (1999) J. Immunol. 162, 4712–4719
44. York, I. A., Mo, A. X. Y., Lemerise, K., Zeng,W. Y., Shen, Y. L., Abraham, C. R., Saric,
Natural N-extended Nested Set of MHC Class I Ligands
6364 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281 • NUMBER 10 • MARCH 10, 2006










T., Goldberg, A. L., and Rock, K. L. (2003) Immunity 18, 429–440
45. Paz, P., Brouwenstijn, N., Perry, R., and Shastri, N. (1999) Immunity 11, 241–251
46. Korber, B. T. M., Brander, C., Haynes, B. F., Koup, R., Moore, J. P., Walker, B. D., and
Watkins, D. (2005) Theoretical Biology and Biophysics Group, pp. LA-UR 06-0036,
Los Alamos National Laboratory, Los Alamos, NM
47. Guo, H. C., Jardetzky, T. S., Garrett, T. P., Lane, W. S., Strominger, J. L., and Wiley,
D. C. (1992) Nature 360, 364–366
48. Fremont, D. H., Matsumura, M., Stura, E. A., Peterson, P. A., andWilson, I. A. (1992)
Science 257, 919–927
49. Speir, J. A., Stevens, J., Joly, E., Butcher, G.W., andWilson, I. A. (2001) Immunity 14,
81–92
50. Probst-Kepper, M., Stroobant, V., Kridel, R., Gaugler, B., Landry, C., Brasseur, F.,
Cosyns, J. P.,Weynand, B., Boon, T., and Van den Eynde, B. J. (2001) J. Exp. Med. 193,
1189–1198
51. Probst-Kepper, M., Hecht, H. J., Herrmann, H., Janke, V., Ocklenburg, F., Klemp-
nauer, J., Van den Eynde, B. J., and Weiss, S. (2004) J. Immunol. 173, 5610–5616
Natural N-extended Nested Set of MHC Class I Ligands
MARCH 10, 2006 • VOLUME 281 • NUMBER 10 JOURNAL OF BIOLOGICAL CHEMISTRY 6365











Yolanda Samino, Daniel López, Sara Guil, Loredana Saveanu, Peter M. van Endert and
Histocompatibility Complex Class I Natural Ligands from HIV Envelope Protein
A Long N-terminal-extended Nested Set of Abundant and Antigenic Major
doi: 10.1074/jbc.M512263200 originally published online January 6, 2006
2006, 281:6358-6365.J. Biol. Chem. 
  
 10.1074/jbc.M512263200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/281/10/6358.full.html#ref-list-1
This article cites 50 references, 28 of which can be accessed free at
 by guest on A
pril 21, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
